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The global HIV pandemic demands an effective 
vaccine. However, while immunogenic vectors 
enter advanced clinical trials, the parameters on 
which to base measurements of efficacious im­
munity in a prospective manner remain unclear. 
Indeed, the recent Merck STEP trial failure has 
exposed our rudimentary understanding of pro­
tective determinants within the adaptive T cell 
response to HIV (1–3). It is established that spe­
cific CD8+ T cell immunity suppresses HIV re­
plication in vivo and that certain patterns with 
respect to antigen targeting and MHC class I   
restriction are consistently associated with low   
levels of virus load (4–6). However, simple qua­
ntitative correlates, at least in peripheral blood, 
have proved elusive (7, 8). This paradox is ex­
emplified by the SIV model, in which CD8+ T 
cell responses to the structurally constrained Gag 
CM9 epitope restricted by Mamu­A*01 are pro­
tective yet insufficient in terms of magnitude 
alone to define outcome (9, 10).
In the absence of consistent numerical cor­
relates of immune control, recent observational 
studies have focused on functional profiling in at­
tempts to identify the properties that demarcate 
effective HIV­specific CD8+ T cell responses 
(11–15). Indeed, a broad consensus indicates that 
polyfunctionality within pathogen­specific T 
cell populations, which is related to the sensi­
tivity of antigen recognition among other pa­
rameters,  correlates  with  improved  outcome 
measures (3, 16). However, the qualitative pro­
perties of CD8+ T cell populations are clearly 
affected by viral replication, and the extent to 
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Despite the pressing need for an AIDS vaccine, the determinants of protective immunity to 
HIV remain concealed within the complexity of adaptive immune responses. We dissected 
immunodominant virus-specific CD8+ T cell populations in Mamu-A*01+ rhesus macaques 
with primary SIV infection to elucidate the hallmarks of effective immunity at the level of 
individual constituent clonotypes, which were identified according to the expression of 
distinct T cell receptors (TCRs). The number of public clonotypes, defined as those that 
expressed identical TCR -chain amino acid sequences and recurred in multiple individu-
als, contained within the acute phase CD8+ T cell population specific for the biologically 
constrained Gag CM9 (CTPYDINQM; residues 181–189) epitope correlated negatively with 
the virus load set point. This independent molecular signature of protection was confirmed 
in a prospective vaccine trial, in which clonotype engagement was governed by the nature 
of the antigen rather than the context of exposure and public clonotype usage was asso-
ciated with enhanced recognition of epitope variants. Thus, the pattern of antigen-spe-
cific clonotype recruitment within a protective CD8+ T cell population is a prognostic 
indicator of vaccine efficacy and biological outcome in an AIDS virus infection.
This article is distributed under the terms of an Attribution–Noncommercial–Share 
Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.jem.org/misc/terms.shtml). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported 
license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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as well as for subdominant responses induced to other viral 
products (18). Notably, these latter CD8+ T cell responses con­
ferred no additional protection in the acute and early chronic 
which such functional associates reflect deterministic attributes 
remains uncertain. Similarly, phenotypic analyses of HIV­spe­
cific CD8+ T cell populations have yet to provide definitive 
indicators of immune control (3). At a more fundamental 
level, a given cognate T cell response is defined by the nature 
of its constituent clonotypes, which are defined on the basis of 
their expressed TCRs and can be considered the elemental 
units of any antigen­specific T cell population. Thus, the pri­
mary interface between the virus and adaptive T cell immu­
nity occurs at the level of TCR­mediated recognition of 
peptide­MHC  antigen;  these  signal  transduction  events,  in 
turn, dictate the ontogeny and biological characteristics of in­
dividual cognate T cells in vivo. Given the seminal importance 
of clonotype­dependent TCR­mediated recognition events, it 
is not unreasonable to propose that the potential efficacy of a 
composite virus­specific CD8+ T cell population might de­
pend on the idiosyncrasies with which individual cognate 
TCRs engage the targeted viral antigen.
In a previous study, we examined the clonotypic composi­
tion of immunodominant CD8+ T cell populations in acute 
SIV infection to illuminate the role of TCR usage in the pro­
cess of mutational immune escape (17). In the present study, 
we conducted a detailed prospective study of vaccine­induced 
SIV­specific CD8+ T cell responses to the same immunodom­
inant epitopes to establish whether the mobilized antigen­spe­
cific TCR repertoire can influence virologic outcome.
RESULTS
Disparate outcomes after vaccination and challenge despite 
induction of potent SIV-specific CD8+ T cell responses
Eight Mamu-A*01+/B*17 rhesus macaques were vaccinated 
with SIVmac239­derived immunogens using a DNA prime/
adenovirus serotype 5 (Ad5) boost regimen and subsequently 
exposed to repeated intrarectal challenges with homologous 
virus until infection occurred (Fig. 1 A). Longitudinal CD4+ T 
cell trajectories and plasma virus load (pVL) dynamics are sum­
marized for all participant macaques in Fig. 1 B. Consistent 
with a previous report that indicated a central role for vaccine­
induced CD8+ T cell responses in the outcome of subsequent 
infection (9), the vaccinated macaques in this study developed 
lower peak and postprimary set point pVL levels and main­
tained memory CD4+ T cells to a greater extent compared 
with control nonvaccinated macaques infected under identical 
conditions (18). Furthermore, although potent SIV­specific 
CD8+ T cell responses were induced by vaccination in all 
cases, virus­specific humoral responses were not a confounding 
factor; no env gene­derived products were incorporated in the 
vaccine formulations, and neutralizing antibodies were de­
tected after infection only in the vaccinee with the least favor­
able course (r97111; Fig. 1 B). However, no significant 
correlations were observed between the magnitude of the vac­
cine­induced CD8+ T cell response to SIV and the degree of 
virologic control after infection; this held for the classically 
immunodominant Mamu­A*01–restricted CD8+ T cell re­
sponses specific for the Tat SL8 (STPESANL; residues 28–35) 
and Gag CM9 (CTPYDINQM; residues 181–189) epitopes, 
Figure 1.  Vaccination regimen and biological outcomes after chal-
lenge. (A) DNA plasmids encoding SIVmac239-derived genes were adminis-
tered i.m. together with adjuvant at weeks 0, 4, and 8, followed at week 24 
by Ad5 vectors encoding the genes described in Materials and methods. 
Repeated weekly intrarectal challenges with SIVmac239 were commenced at 
week 50 and continued until infection occurred, as determined by pVL mea-
surements 7 d later. (B) Longitudinal pVL measurements (top) and peripheral 
blood CD4+ T cell counts (bottom) are shown for each macaque over a 500-d 
time period from infection; the symbol color code for each macaque is 
shown. (C) The frequency of CM9 and SL8 pMamu-A*01 tetramer+ CD8+  
T cells is shown for each macaque at week 2 after vaccination with Ad5 and 
at week 4 after infection; the color code corresponds to that in B.JEM VOL. 206, April 13, 2009 
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were generally more polyclonal (median = 16.5 clonotypes; 
range = 10–38 clonotypes) than the corresponding CM9­spe­
cific populations (median = 8 clonotypes; range = 2–16 clono­
types). Overall, these characteristics are remarkably analogous to 
those observed in primary SIV infection (17), thereby indicating 
that the intrinsic nature of cognate antigen rather than the con­
text of presentation is a primary determinant of clonotype re­
cruitment in the periphery.
Vaccine-induced SIV epitope–specific CD8+ T cell clonotypes 
are maintained and expanded during acute SIV infection
The CD8+ T cell responses mounted after SIVmac239 infection 
were substantially greater in magnitude and mobilized with faster 
kinetics compared with the corresponding epitope­specific re­
sponses in nonvaccinated controls (18). Within these anamnestic 
responses, which were generally expanded compared with those 
induced by vaccination (Fig. 1 C), a notable degree of clono­
typic preservation was apparent for both SL8­specific (Fig. S1) 
and CM9­specific (Fig. 2) CD8+ T cell populations. Indeed, 
conservation of clonotype usage was apparent in longitudinal 
follow­up studies of macaques r96133 and r97113 beyond week 
4 after infection (Fig. 3 and not depicted). This is consistent with 
a previous study in humans, in which vaccine­induced clono­
types specific for the HLA B*2705–restricted HIV­1 p24 Gag 
KK10 epitope (KRWIILGLNK; residues 263–272) were well 
represented after infection (21). However, there was also a high 
degree of clonotype turnover between the PV and PI time 
points, with evident recruitment of new clonotypes and loss of 
vaccine­primed clonotypes in both the SL8­ and CM9­specific 
CD8+ T cell populations (Fig. S1 and Fig. 2); similar shifts in 
clonotypic composition were observed in a recent study of vac­
cinated pigtail macaques (22) and tend to characterize the natural 
evolution of immunodominant CD8+ T cell responses in both 
HIV and SIV infection (12, 17). Overall, the immunodominant 
primary SIV­specific CD8+ T cell populations characterized in 
the present cohort exhibited significantly less diversity at the clo­
notypic level than the corresponding repertoires in nonvacci­
nated macaques at a similar time point after infection (P = 0.03 
for SL8/TL8, and P = 0.008 for CM9 using the Mann­Whitney 
U test comparing Simpson’s diversity indices with standardization 
for clone sample size) (23). Although we cannot unequivocally 
attribute repertoire narrowing to antigen preexposure during 
immunization, it is salutary to anticipate that such reductions in 
clonotypic diversity might adversely complicate vaccination by 
facilitating viral escape (17, 24).
Public clonotype usage in primary Gag CM9–specific  
CD8+ T cell populations predicts the outcome of SIV infection
Evidence from vaccination studies indicates a protective role for 
the Mamu­A*01–restricted CM9­specific CD8+ T cell response 
(9); this is consistent with experiments demonstrating that strict 
biological constraints operate in this region of the virus and limit 
the potential for escape through antigenic mutation (25, 26). We 
therefore hypothesized that the clonotypic constitution of CM9­
specific CD8+ T cell populations could determine virologic out­
come in macaques infected with SIV. Initially, we explored this 
phases of SIV infection when compared with Gag vaccina­
tion alone using the same platform (9, 18). Thus, this cohort 
encapsulates the conundrum that while the presence of a re­
sponse is clearly beneficial, the precise attributes of the induced 
CD8+ T cell populations that confer protection remain obscure.
Vaccine- and infection-induced SIV epitope–specific  
CD8+ T cell populations exhibit similar clonotypic profiles
The observation that disparate outcomes were not dependent 
on simple quantitative measures of response magnitude alone 
prompted us to seek qualitative determinants of CD8+ T cell–
mediated immune protection in this cohort. Given that down­
stream cellular effector functions originate from the initial 
interaction between TCR and cognate peptide–MHC class I 
antigen, we first examined the clonotypic architecture of   
immunodominant SIV­specific CD8+ T cell populations. In 
each macaque, the dominant response 2 wk after boosting with 
Ad5 vectors (the postvaccination [PV] time point) was directed 
against the CM9 epitope (Fig. 1 C); this is consistent with an­
tigen targeting patterns observed in Mamu-A*01+ macaques 
during primary SIV infection but with substantial skewing 
away from the typically codominant SL8 epitope (19). After 
infection, the vaccinated macaques mounted massive anam­
nestic CD8+ T cell responses to the SL8 and CM9 epitopes 
that together comprised >50% of the total acute phase SIV­
specific CD8+ T cell population (18). Cognate SL8­ and 
CM9­specific CD8+ T cells were visualized directly ex vivo 
with fluorochrome­conjugated pMamu­A*01 tetrameric 
complexes and sorted viably by flow cytometry at both the PV 
time point and 4 wk after infection (the postinfection [PI] time 
point); an anchored template­switch RT­PCR that reproduc­
ibly generates an accurate hierarchical representation of TCRB 
gene expression was then used to ascertain the clonotypic 
composition of each sorted population (17). The amino acid 
sequences of all expressed TCRB CDR3s at both time points 
are shown for the SL8­specific clonotypes in Fig. S1 and for 
the CM9­specific clonotypes in Fig. 2. Strikingly, both vac­
cine­induced antigen­specific CD8+ T cell populations in all 
eight macaques exhibited clonotypic profiles similar to those 
observed in a previous study of acute SIV infection (17). In 
particular,  the  SL8­specific  clonotypes  expressed  predomi­
nantly TCRBV14 and TCRBJ1.5 in association with a re­
stricted  CDR3  motif  characterized  by  the  presence  of  an 
arginine residue at position 6 (Fig. S1), whereas the CM9­spe­
cific clonotypes exhibited greater CDR3 diversity and a pre­
ference for TCRBV13 (Fig. 2). Furthermore, CD8+ T cell 
populations of both specificities elicited by vaccination exhib­
ited the phenomenon of TCRB “sharing” between different 
macaques (Fig. S1 and Fig. 2); all common TCRB CDR3 se­
quences were encoded with distinct interindividual nucleotide 
profiles and restricted to the relevant antigen specificity across 
the entire dataset (Table S1 and Table I). Such public clonotypes 
(20) are defined in this study on the basis of CDR3 and TCRBJ 
identity because of minor 5 regional variations between detected 
TCRBV13 sequences (Table S2) and were more prevalent in the 
motif­dominated SL8­specific CD8+ T cell populations, which 926 CLONOTYPIC DETERMINANTS OF PROTECTIVE CD8+ T CELL RESPONSES | Price et al.
possibility retrospectively using data reported in a previous study 
of 12 rhesus macaques acutely infected with SIVmac251 (17). 
Among several candidate measures of clonal composition at week 
5 after infection, the best predictor of postprimary set point pVL 
proved to be the number of public clonotypes within the CM9­
specific CD8+ T cell population (P = 0.0006 and r2 = 0.71;   
Figure 2.  Clonotypic architecture of CM9-specific CD8+ T cell populations. TCRB CDR3 amino acid sequences, TCRBV and TCRBJ usage, and the 
relative frequency of CD8+ T cell clonotypes specific for the CM9 epitope are shown for all eight macaques at week 2 after vaccination with Ad5 (left) and 
at week 4 after infection with SIVmac239 (right). The number of challenges required for infection to occur is indicated in each case underneath the indi-
vidual macaque identification codes. Data are separated according to macaques with the lowest (A) and highest (B) set point pVL values. Colored boxes in 
the frequency column (percentages) indicate clonotypes within individual macaques that have the same TCRB CDR3 amino acid sequence at both time 
points shown; colored boxes in the CDR3 sequence column indicate public clonotypes. Public clonotypes were defined on the basis of TCRB amino acid 
sequences that were present in more than one macaque; TCRB sequences reported both in this study and in a previous study were included in the analysis 
(reference 17). The corresponding TCRB CDR3 nucleotide sequences are shown in Table I.JEM VOL. 206, April 13, 2009 
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Table I.  CM9-specific public clonotype TCRB CDR3 nucleotide alignments
CDR3 codon usage of CM9-specific CD8+ T cell public clonotypes. Each section displays a distinct TCRB CDR3 amino acid sequence, and the nucleotide alignments for all 
corresponding clonotypes in each macaque. Public clonotypes were defined on the basis of TCRB amino acid sequences that were present in more than one macaque; 
previously reported TCRB sequences were included in this analysis (reference 17). 1–6: time points from PV for macaques r97113 and r96133 (1 is PV, and 2–6 are subsequent 
blood draws as shown in Fig. 3).
Fig. 4 A and not depicted); this parameter is solely a measure of 
interindividual  clonotype  sharing  within  the  antigen­specific 
repertoire and is distinct from both clonal diversity and TCR 
sequence. Multivariate linear regressions were also considered 
using stepwise model building to test for the influence of other 
potentially predictive parameters; such variables included   928 CLONOTYPIC DETERMINANTS OF PROTECTIVE CD8+ T CELL RESPONSES | Price et al.
Figure 3.  Longitudinal analysis of clonotypic structure in macaques r97113 and r96133. (A, top) pVL (SIV RNA copies/ml) and CD4+ T cell count 
(cells/µl) in macaque r97113 at the indicated time points; (bottom) number and relative frequency of individual T cell clonotypes, with monoclonal popula-
tions defining the narrowest clonotypic structure, specific for CM9 (red bars) and SL8 (blue bars). (B) The usage of public (dark shading) and private (light 
shading) clonotypes in the CD8+ T cell populations specific for CM9 (red; left) and SL8 (blue; right) in macaque r97113 at the indicated time points; the 
number of public clonotypes over total clonotypes is shown at each time point. (C) Experiments performed as in A for macaque r96133. (D) Experiments 
performed as in B for macaque r96133.JEM VOL. 206, April 13, 2009 
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the cognate response (17, 18, 29–31). Thus, although SL8/TL8­
specific CD8+ T cell populations are typically polyclonal in acute 
SIV infection and exhibit a substantial degree of TCR sharing 
(Fig. S1 and Fig. 3), they are neither protective nor clonotypi­
cally diverse (17, 30). Instead, the monomorphic nature of SL8/
TL8­specific TCRs, which presumably require a TCRB CDR3 
motif to engage a relatively featureless antigen regardless of inter­
individual sharing (32), predisposes to viral escape at the level of 
TCR recognition (17); this contrasts with the diverse range of 
clonotypes that can be mobilized in response to the CM9 epit­
ope, and in the face of such considerations, the clonotypic com­
position of the SL8/TL8­specific response with respect to the 
degree of TCR sharing becomes largely irrelevant. Public clo­
notype usage can therefore be associated with either favorable or 
unfavorable biological outcomes according to the nature of the 
targeted epitope and the characteristics of the available cognate 
repertoire. Consequently, it is important to emphasize that the 
absolute CD4+ and CD8+ T cell counts, mean log10 pVL at time 
points before week 6, and additional measures of clonality such 
as the total number of clonotypes and the proportion of the re­
sponse that comprised public clonotypes. None of these covari­
ates lead to a model that was significantly more predictive of 
postprimary set point pVL (i.e., mean log10 pVL from week 6 
to 16) than the simple model based on the number of public 
clonotypes (unpublished data). Similarly, the inclusion of these 
other variables did not substantially change estimates of the rela­
tionship between the number of public clonotypes and postpri­
mary set point pVL. Furthermore, the results were unaffected by 
small changes in parameterization of the response variable, such 
as modeling the mean log10 pVL or using the area under the 
curve from week 10 to 16, or by altering the definition of public 
clonotype at the amino acid level as follows: (a) matching 
TCRBV, TCRB CDR3, and TCRBJ; (b) matching TCRB 
CDR3 and TCRBJ; and (c) matching TCRB CDR3 alone. 
Subsequently, we tested the hypothesis generated from this anal­
ysis using the dataset described in this study; indeed, the rationale 
for the current study was based on the initial finding, and this 
second  stage  was  conducted  prospectively  with  investigator 
blinding. There was a significant inverse relationship between 
the number of public clonotypes at week 2 after vaccination and 
the mean log10 pVL from week 6 to 16 (Pearson: r = 0.81 
and P = 0.014; Spearman: r = 0.82 and P = 0.015). The lin­
ear regression parameter (slope = 0.55) indicates that the esti­
mated effect of each public clonotype was a mean reduction in 
postprimary pVL of 0.55 log10 RNA copies/ml during this pe­
riod (Fig. 4 B). Notably, no such correlation with outcome was 
observed for clonal diversity per se (Pearson: P = 0.11) despite a 
strong association between this parameter and the number of 
public clonotypes (Pearson: r = 0.85 and P = 0.007; diversity of 
clonotypes  with  standardization  for  clone  sample  size)  (23). 
There was no significant relationship between the number of 
public clonotypes at week 4 after infection and mean log10 pVL 
from week 6 to 16 (Pearson: P = 0.92). As described, no other 
measures of clonality were significant predictors of postprimary 
set point pVL, either alone or as covariates (unpublished data); 
similarly, we could find no clonotypic correlates of either central 
memory CD4+ T cell preservation (18, 27, 28) or the number 
of challenges required for infection to occur. Finally, to validate 
the association further, the original cohort was revisited with 
public clonotypes assigned according to the same definition but 
compiled using the entire dataset from all 20 macaques. This ex­
panded range for the number of public clonotypes exerted only 
a minimal influence on a simple linear regression performed 
against mean log10 pVL from week 6 to 16 (P = 0.007 and r2 = 
0.54). In all analyses, results using the computed area under the 
pVL trajectory curve from week 6 to 16 were consistent with 
those derived using the mean pVL for the same period. No sig­
nificant correlations were observed for parallel analyses of SL8/
TL8­specific CD8+ T cell clonotypes in either dataset (unpub­
lished data); these negative findings act as an important control 
and are not unexpected given the propensity with which the in­
fecting virus mutates at this site with minimal biological con­
straints to evade immune recognition and curtail the efficacy of 
Figure 4.  The number of public clonotypes in primary Gag CM9–
specific CD8+ T cell populations predicts virologic outcome in SIV 
infection. Simple linear regressions predicting mean log10 pVL from 
week 6 to 16 after infection by the number of public clonotypes present 
in the CM9–specific CD8+ T cell population at week 5 after infection 
without prior vaccination in a previously reported cohort of 12 ma-
caques (A; reference 17) and at week 2 after vaccination in the cohort of 
macaques described in this study (B). In A, the relationship remained 
highly significant with minimal change in the coefficient when the most 
influential data point was discarded from the analysis; the analysis pre-
sented in B was performed to confirm the relationship observed in A.930 CLONOTYPIC DETERMINANTS OF PROTECTIVE CD8+ T CELL RESPONSES | Price et al.
predictive value of “publicity” within epitope­specific CD8+ T 
cell responses is context dependent.
Public clonotype usage does not skew the phenotypic 
properties or functional capabilities of composite  
antigen-specific CD8+ T cell populations
To investigate the mechanistic basis for the observed clonotypic 
association with virologic outcome, we attempted to discern the 
biological properties conferred by public TCR usage that distin­
guish such T cells from those with identical antigen specificity 
derived from the private repertoire. Initially, we reasoned that 
differential TCR/pMamu­A*01 engagement might trigger 
subtly different cellular outputs in the composite antigen­spe­
cific T cell populations. Indeed, recent studies linking the func­
tional attributes of HIV­specific CD8+ T cells to pVL in infected 
individuals provide a potential precedent for such a link (3, 11, 
12, 14). We therefore assessed the functional output of CM9­
specific CD8+ T cell populations in macaques r96133 and 
r97113 at the prechallenge time point, thereby excluding any 
confounding impact of replicating SIV on these cells. These ma­
caques were selected on the basis that they epitomize the associa­
tion expounded in the present study; specifically, despite similar 
levels of clonal diversity, r97113 had a favorable outcome after 
infection and a CD8+ T cell response to CM9 that was predomi­
nantly public, whereas the opposite applied to r96133 (Figs.   
2 and 3). In each case, both IFN­ and TNF­ production were 
triggered in response to antigen with almost identical peptide 
sensitivities for the former effector function (Fig. 5, A–C). 
Screening for additional soluble factors released on antigen 
encounter yielded similarly uniform results overall, although 
PBMCs from r96133 failed to produce significant levels of MIP­
1 and were comparatively meager with respect to lymphotoxin 
A secretion (Fig. 5 B). Furthermore, these vaccine­induced 
CD8+ T cell populations exhibited indistinguishable effector 
memory (CD28CD45RA+CD95+) phenotypic profiles 
(Fig. 5 D); interestingly, this suggests that the impaired matura­
tional profile characteristic of HIV­specific CD8+ T cells in in­
fected individuals arises as a consequence of virus exposure (33, 
34). Thus, consistent with the findings of a recent mouse study 
(35), no major disparities were apparent in the interactions of 
these constitutively distinct CM9­specific CD8+ T cell popula­
tions with cognate wild­type antigen. Functional and pheno­
typic homogeneity irrespective of clonotypic composition was 
also observed in multiparametric analyses of CM9­specific CD8+ 
T cell populations at the PI time point (n = 6; Fig. S2 and not 
Figure 5.  Functionality, antigen sensitivity, and immunophenotype 
of CM9-specific CD8+ T cell populations. Data from the prechallenge 
time point are shown for macaques r96133 (A, C, and D, left; B, red) and 
r97113 (A, C, and D, right; B, green). (A) Intracellular production of IFN- 
and TNF- after direct ex vivo stimulation of PBMCs with CM9 peptide at 
a concentration of 2 µg/ml. Plots are gated on CD3+CD8+ cells. Corre-
sponding background values in the absence of cognate peptide, expressed 
with respect to the total CD8+ memory T cell pool, were 0.05 and 0.02% 
for IFN-, 0.46 and 0.22% for TNF-, and 0.15 and 0% for IFN-/TNF-, 
respectively, for macaques r96133 and r97113. (B) PBMCs were stimulated 
with CM9 peptide at a concentration of 2 µg/ml and assayed for produc-
tion of the indicated soluble factors by cytokine bead array. Results are 
shown with background subtracted. (C) PBMCs were stimulated with CM9 
peptide at the concentrations indicated in an IFN- ELISPOT assay. Results 
are shown with background subtracted. (D) Phenotypic profiles, as defined 
by expression of CD28 and CD45RA, of CM9 pMamu-A*01 tetramer+ CD8+ 
T cells. Plots are gated on CD3+CD8+CD95+ cells; the CM9 pMamu-A*01 
tetramer+ events are shown as red dots superimposed on a density plot 
showing the phenotype of all gated cells. Similar phenotypic profiles were 
observed in the functionally responsive cells identified in A (not depicted). 
MFI, mean fluorescence intensity; SFC, spot-forming cell.
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depicted). Collectively, these data suggest that such approaches 
are insufficient in isolation to monitor the efficacy of T cell re­
sponses with respect to biological outcome.
Antigen-specific CD8+ T cell populations comprising 
multiple public clonotypes exhibit promiscuous variant 
antigen recognition properties
Given the absence of obvious functional or phenotypic differ­
entiators between public and private CM9­specific responses 
with respect to wild­type antigen, we reasoned that differential 
recognition properties might be apparent in response to variant 
antigens. Cross­reactivity is an intrinsic property of the T cell 
recognition system (36) and has potentially important biologi­
cal consequences (37, 38). Faced with a persistent, genetically 
unstable pathogen, antigen­specific CD8+ T cell populations 
with enhanced variant recognition capabilities might enable 
more efficacious immune control (39); such cross­reactivity 
could be achieved either by clonotypic diversity (17, 40–42) or 
by the incorporation of highly promiscuous clonotypes within 
the composite population (43–45). We tested this possibility in 
macaques r96133 and r97113, selected on the basis of a robust 
and consistent distinction in terms of public clonotype usage 
(Figs. 2 and 3), using IFN­ ELISPOT analysis of PBMCs 
from the prechallenge time point (Fig. 6); importantly, the dis­
crete but related parameter of activation threshold per se was 
not a confounder in these experiments because recognition sen­
sitivities for wild­type antigen were almost identical (Fig. 5 C). 
All possible amino acid substitutions were tested at positions 1, 
7, and 8 in the CM9 peptide; these are potential TCR contact 
residues that have previously been shown by alanine scanning 
experiments to be the only intraepitopic sites tolerant of vari­
ability within the confines of viral fitness, although replication 
competence is affected to a substantial extent in the case of P7 
mutations (26). Notably, a greater degree of recognition flexi­
bility was apparent in the public clonotype–dominated CM9­
specific CD8+ T cell population from macaque r97113 (Fig. 6). 
Similar results were observed in additional macaques with dia­
metrically opposed patterns of CM9­specific clonotype usage 
(Fig. S3 and not depicted); interestingly, some public clono­
type–rich CM9­specific CD8+ T cell populations exhibited en­
hanced recognition of variants relative to wild­type antigen. The 
extent to which individual variants were recognized by public 
versus private clonotypes could not be assessed in these experi­
ments due to limiting cell numbers. However, CD8+ T cells 
specific for the CM9 variants L1 and M8 sorted from macaque 
r97113 with pMamu­A*01 tetrameric complexes refolded 
around the relevant peptides demonstrated almost identical clo­
notypic compositions to the corresponding wild­type CM9­
specific population; these data exclude the possibility that the 
observed cross­reactivity was mediated by clonotypically distinct 
CD8+ T cell populations (unpublished data). Thus, public   
Figure 6.  Sensitivity of CM9-specific CD8+ T cell populations to 
epitope variants. PBMCs from macaques r97113 (top) and r96133 (bot-
tom) at the prechallenge time point were stimulated in IFN- ELISPOT 
assays with CM9 wild-type peptide or individual peptides containing 
each possible amino acid substitution at positions P1, P7, and P8; mu-
tations at these positions can be incorporated either with minimal im-
pact on viral fitness (P1 and P8) or without disabling the virus entirely 
(P7; reference 26). Each peptide was assayed at a concentration of  
107 M, selected on the basis of the titrations shown in Fig. 5 C; broader 
screening was precluded by limiting cell numbers. The CM9 sequence is 
shown at the top and the substituted amino acid in each position is 
shown on the left of each panel. Data are color coded to indicate the 
size of the response to the variant epitope as a percentage of the re-
sponse to the CM9 wild-type peptide.
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quence of convergent recombination (20, 47–49). Indeed, it is 
tempting to speculate that this process establishes an “immuno­
logical homunculus” (50) within the naive T cell pool com­
prising highly prevalent public T cell clonotypes with a 
proclivity for cross­reactivity that can expand rapidly in re­
sponse to a substantial number of antigenic assaults and thereby 
provide an early protection system against many pathogens. 
This scenario is consistent with several observations. First, it 
could explain the classical early immunodominance of the 
SL8/TL8 epitope in Mamu-A*01+ macaques during acute SIV 
infection (19); SL8/TL8­specific CD8+ T cell populations are 
dominated by public clonotypes bearing a TCRB CDR3 co­
don­degenerate motif (17), and a high presursor frequency 
of such TCRs generated through convergent recombination 
could fuel primary responses to this antigen. Indeed, the SL8­
specific response is markedly less dominant after infection in 
the presence of vaccine­induced CD8+ T cell populations 
specific for other epitopes (Fig. 1) (18), further supporting the 
notion that TCR repertoire skewing underlies this pattern of 
immunodominance. Second, the associations between public 
clonotype usage and virologic outcome were only apparent at 
the initial point of antigen contact (the PV time point in the 
vaccination study and week 5 after infection in the unmanipu­
lated acute SIV cohort); although the publicity of individual 
responses was maintained to some extent throughout the pe­
riod of study (Fig. 3), these correlations were lost at later time 
points (the PI time point and week 12 after infection, respec­
tively). Thus, consistent with an effect mediated by the pre­
dominance of cognate public clonotypes within the naive T 
cell pool, it seems that the nature of the primary interactions is 
determinant and that the initially relevant clonal topography is 
obscured with subsequent adaptation to persistent antigen (51). 
Third, recruitment of all cognate clonotypes, both public and 
private, during the vaccination process is likely to mask any 
advantage conferred by high precursor frequencies in the naive 
T cell pool; these considerations could explain the lack of asso­
ciation between public clonotype usage and virologic outcome 
at the PI time point, and the weaker correlation at the PV time 
point with respect to the acute infection cohort. Overall, these 
considerations invoke subtle differences in the nature of the 
primary CD8+ T cell response as profound determinants of 
outcome (52). However, ongoing recruitment of antigen­spe­
cific CD8+ T cells from a munificent naive pool may continue 
to sustain a more effective response throughout the course of 
infection (53); in this regard, the correlation between clono­
typic diversity and the number of public clonotypes is notable 
despite the fact that the latter parameter in isolation did not 
achieve significance with respect to measures of disease pro­
gression in the present study.
In summary, these data provide compelling evidence that 
the fundamental nature of the initial encounter between a con­
strained viral antigen and the adaptive cellular immune system 
dictates subsequent biological outcome. The potential for vac­
cine­based initiatives to alter such interactions with beneficial 
effect will likely depend on the balance between the extent to 
which differential public clonotype usage is predetermined by 
clonotype usage is associated with enhanced cross­reactivity to 
potentially relevant antigenic variants.
DISCUSSION
In the present study, we conducted a detailed analysis of anti­
gen­specific CD8+ T cell clonotype usage in relation to viro­
logic outcome in acute SIV infection. A strong immunological 
correlate of protection was identified, in which set point pVL 
was negatively associated with the number of public clono­
types present within the initially mobilized Gag CM9–specific 
CD8+ T cell population. Subsequently, we tested this associa­
tion prospectively in a vaccine trial. Again, the number of 
public clonotypes in the vaccine­induced CM9­specific CD8+ 
T cell population correlated inversely with virologic outcome 
after SIV challenge. Compared with private clonotype–domi­
nated CM9­specific CD8+ T cell responses, populations with 
substantial public clonotype representation exhibited greater 
levels of cross­reactivity to epitope variants at virologically 
permissive residues despite comparable activation thresholds 
and equivalent clonal diversity; these data establish the testable 
hypothesis that public clonotypes are intrinsically more pro­
miscuous than private clonotypes. In contrast, phenotypic pro­
files and functional properties elicited in response to wild­type 
antigen were largely similar regardless of clonotypic architec­
ture, although it remains possible that important differences 
might emerge from more extensive analyses. Thus, the nature 
of the initial interactions between virus and emergent anti­
gen­specific CD8+ T cell clonotypes is an independent pre­
dictor of outcome in SIV infection.
Mechanistically, the observed association between public 
clonotype usage and enhanced cross­reactivity profiles is 
somewhat at odds with the finding that the contingent protec­
tive effect is apparent immediately after infection. The CM9 
epitope is generally stable throughout the early periods of in­
fection, with escape mutants appearing late and variably; in­
deed, no CM9 mutations were detected within the course of 
this study (macaques r00060 and r01008; unpublished data). 
How can we explain this apparent discrepancy? One possibil­
ity is that emerging escape mutations below the level of detec­
tion or at anatomically disparate sites are quelled more 
effectively by public clonotypes and that these imperceptible 
events favorably influence other facets of host immunity and, 
hence, the subsequent outcome of infection. Alternatively, 
public clonotype usage might be linked to a distinct determi­
nant of virologic control, with enhanced variant recognition 
simply representing an epiphenomenon. For example, the ki­
netics with which cognate T cells are mobilized from the na­
ive pool in response to incoming virus could dramatically 
modify the massive pathological damage that can occur during 
acute SIV infection (46), and thereby associate better down­
stream virologic outcomes with more pronounced public clo­
notype content if the latter are preferentially recruited into 
earlier and more robust CM9­specific CD8+ T cell popula­
tions. Mechanistically, such a selective priming bias could oc­
cur as a function of precursor frequency, and it does appear 
that public clonotypes are generated more often as a conse­JEM VOL. 206, April 13, 2009 
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parallel negative controls without cognate peptide were included. Subsequent 
staining procedures to exclude aberrant binding events, identify surface mark­
ers, and detect intracellular cytokine production or granzyme B content were 
conducted as previously described with minor modifications (62). For phe­
notypic analyses of pMamu­A*01–allophycocyanin (APC) tetramer–labeled 
cells, the following directly conjugated mAbs were used: anti­CD3–Cy7APC, 
anti­CD8–Pacific blue, anti­CD28–FITC, anti­CD45RA–Texas red–PE, and 
anti­CD95–Cy5PE. At least 106 events were acquired on an LSR II flow cy­
tometer (BD) equipped for the detection of 17 fluorescent parameters, and 
data were analyzed with FlowJo software (Tree Star, Inc.). In all cases, elec­
tronic compensation was performed with antibody­capture beads (BD) stained 
separately with individual mAbs present in the experimental samples. Flow cy­
tometric cell sorting was conducted with a modified FACSAria (BD) at 70 
PSI; postsort purity was consistently >98%.
Clonotype analysis. Tetramer­labeled CD8+ T cells were sorted viably 
into 1.5­ml microtubes containing 100 µl RNAlater (Applied Biosystems); 
for the CM9­specific populations in this study, the median number of 
sorted cells was 5,000 (range = 740–10,000). All expressed TCRB gene 
products were amplified without bias using an anchored template­switch 
RT­PCR (17, 41); amplicons were subcloned, sampled, sequenced, and 
analyzed as previously described (17, 63). For consistency with previous 
studies, Arden’s nomenclature is retained throughout (64); macaque TCRBV 
and TCRBJ sequences were assigned according to the closest human 
equivalent (17).
Statistics. The presented analysis comprised hypothesis generation and 
confirmation as two distinct steps. First, the relationship between several 
candidate measures of SIV antigen­specific CD8+ T cell repertoires at week 
5 after infection and mean postprimary pVL from week 6 to 16 was   
explored using simple linear regressions in an analysis restricted to data 
derived  from  a  previous  study  of  SIVmac251  infection  (17).  Due  to   
heteroskedasticity, a logarithmic scale was used for pVL data. Variables con­
sidered included the total number of unique clonotypes (diversity), the total 
number of public clonotypes, and the percentage of captured clonotypes 
that were public; these parameters were assessed both as absolute values and 
in relation to response magnitude. The number of public clonotypes at 
week 5 after infection emerged as the strongest predictor of mean pVL dur­
ing the later interval. Further multivariate linear regression models were 
considered to examine the independence of this predictive variable, to as­
sess whether predictions could be significantly improved with combinations 
of variables, and to determine the impact of additional variables on the ob­
served relationships. Second, an independent dataset was collected from the 
cohort of eight macaques as described in this study; this information was 
used to test the hypothesis generated in the first step. Simple linear regres­
sions were used as the primary models to relate the number of public clo­
notypes,  identified  both  within  this  cohort  and  in  relation  to  the  first 
cohort, at both week 2 after vaccination and week 4 after infection to mean 
log10 pVL from week 6 to 16 after infection. As the time points at which 
pVL was measured were not quite evenly spaced, we also computed the 
area under the curve from week 6 to 16 and repeated the linear regressions 
with this variable. For thoroughness, the alternative measures described 
previously were also examined in the second cohort. In a final step, we re­
turned to the first cohort of macaques with the expanded compilation of 
public clonotypes based on the incorporation of data from the second co­
hort to confirm that the observed relationships were maintained.
Online supplemental material. Fig. S1 shows the clonotypic architec­
ture of SL8­specific CD8+ T cell populations at week 2 after vaccination 
with Ad5 and at week 4 after infection with SIVmac239; the corresponding 
nucleotide sequences are displayed in Table S1. Fig. S2 presents a functional 
analysis of CM9­specific CD8+ T cell populations from six macaques in 
the acute phase after infection; based on the simultaneous and independent 
measurement of five separate effector functions directly ex vivo in a flow 
cytometric panel comprising 13 distinct parameters, no significant differences 
the composition of naive pool (54), or perhaps even the het­
erologous memory pool (37), versus stochastic elements in 
the initial antigen­specific selection process. Further studies 
are necessary to clarify the associations described in this pa­
per, especially with respect to mechanistic determinants at 
the clonal level and quantitative relationships at the sites of 
active viral replication. However, the observation that clono­
typic parameters can predict virologic outcome provides am­
ple reason to consider such effects in the design and monitoring 
of vaccine efficacy trials.
MATERIALS AND METHODS
Vaccination and infection procedures. All animals in this study were 
colony­bred Mamu-A*01+ Indian rhesus macaques (Macaca mulatta). Vacci­
nation studies were approved by the Institutional Animal Care and Use 
Committee at the University of Wisconsin and were conducted in full ac­
cordance with established regulations and guidelines using a DNA prime/
adenovirus boost platform, as previously described (55). In brief, 5 mg of a 
VIR vector DNA construct containing codon­optimized SIVmac239 gag, 
tat, rev, or mutated nef genes was added to 7.5 mg CRL1005 (CytRx) mixed 
with benzalkonium chloride (Ruger). Eight Mamu-B*17 macaques were 
vaccinated intramuscularly (i.m.) with 0.5 ml of each DNA preparation at 
weeks 0, 4, and 8. At week 24, recombinant E1­deleted replication­incom­
petent Ad5 vectors containing the same individual SIVmac239 genes were 
injected i.m. at a dose of 1011 recombinant viral particles. All vaccines were 
administered at four separate sites, one for each SIVmac239 gene insert (18). 
Intrarectal challenges with SIVmac239 (300 TCID50) were started at week 
50 (56); infection occurred after two to seven weekly challenges (18). Infec­
tion studies with SIVmac251 were previously described (17). The Mamu­
A*01–restricted Tat epitope (residues 28–35) differs at position 1 between 
SIVmac239 (SL8) and SIVmac251 (TL8); the corresponding Gag epitope 
(residues 181–189) is identical in both strains (CM9).
Virus load quantification. pVL was determined for all SIVmac239 studies 
using previously published protocols (57, 58) with minor modifications (18).
IFN- ELISPOT assays. Direct ex vivo production of IFN­ in response 
to stimulation of PBMCs with the concentrations of wild­type CM9 peptide 
or variants thereof indicated in the figures was assessed in ELISPOT assays, 
as previously described (59, 60). All conditions were tested in duplicate. Spot 
imaging and quantification were automated with an ImmunoSpot Series 3B 
Analyzer (CTL Analyzers LLC). Background counts in the absence of exog­
enous peptide were subtracted from experimental counts; for comparative 
analyses, results were calculated as the percentage of spots induced by variant 
peptide with respect to wild type.
Cytokine bead arrays. Direct ex vivo production of multiple soluble 
factors in response to stimulation with wild­type CM9 peptide at a con­
centration of 2 µg/ml was assayed using the Cytokine Bead Array Flex Set 
(BD) containing mAbs and detection reagents specific for 25 different 
cytokines, each of which was shown in preliminary experiments to cross 
react with rhesus macaque cytokines. Unstimulated samples were used in 
parallel to determine background levels of cytokine secretion resulting 
from in vivo activation; these values were subtracted from the data shown 
in Fig. 5 B.
Flow cytometry and cell sorting. Soluble fluorochrome­labeled pMamu­
A*01 tetramers were produced and used as previously described (17, 61). For 
functional analyses of CD8+ T cell populations, 2 × 106 PBMCs were stimu­
lated with cognate peptide at a final concentration of 2 µg/ml in R10 medium 
(RPMI 1640 supplemented with 10% heat­inactivated fetal calf serum, 100 
U/ml penicillin, 100 µg/ml streptomycin, and 2 mM l­glutamine) for 6 h in 
the presence of 5 µg/ml anti­CD28–Alexa Fluor 680 mAb, 10 µg/ml anti­
CD49d mAb, and 10 µg/ml brefeldin A; for each experimental condition, 934 CLONOTYPIC DETERMINANTS OF PROTECTIVE CD8+ T CELL RESPONSES | Price et al.
by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 
204:2473–2485. 
  13.  Lichterfeld, M., X.G. Yu, S.K. Mui, K.L. Williams, A. Trocha, M.A. 
Brockman, R.L. Allgaier, M.T. Waring, T. Koibuchi, M.N. Johnston, 
et al. 2007. Selective depletion of high­avidity human immunodeficiency 
virus type 1 (HIV­1)­specific CD8+ T cells after early HIV­1 infection.   
J. Virol. 81:4199–4214. 
  14.  Daucher, M., D.A. Price, J.M. Brenchley, L. Lamoreaux, J.A. Metcalf, 
C.  Rehm,  E.  Nies­Kraske,  E.  Urban,  C.  Yoder,  D.  Rock,  et  al. 
2008. Virological outcome after structured interruption of antiretrovi­
ral therapy for human immunodeficiency virus infection is associated 
with the functional profile of virus­specific CD8+ T cells. J. Virol. 
82:4102–4114. 
  15.  Rehr, M., J. Cahenzli, A. Haas, D.A. Price, E. Gostick, M. Huber, 
U. Karrer, and A. Oxenius. 2008. Emergence of polyfunctional CD8+ 
T cells after prolonged suppression of human immunodeficiency virus 
replication by antiretroviral therapy. J. Virol. 82:3391–3404. 
  16.  Seder, R.A., P.A. Darrah, and M. Roederer. 2008. T­cell quality in mem­
ory and protection: implications for vaccine design. Nat. Rev. Immunol. 
8:247–258. 
  17.  Price, D.A., S.M. West, M.R. Betts, L.E. Ruff, J.M. Brenchley, D.R. 
Ambrozak, Y. Edghill­Smith, M.J. Kuroda, D. Bogdan, K. Kunstman, 
et al. 2004. T cell receptor recognition motifs govern immune escape 
patterns in acute SIV infection. Immunity. 21:793–803. 
  18.  Wilson, N.A., J. Reed, G.S. Napoe, S. Piaskowski, A. Szymanski, J. Furlott, 
E.J. Gonzalez, L.J. Yant, N.J. Maness, G.E. May, et al. 2006. Vaccine­ 
induced cellular immune responses reduce plasma viral concentrations after 
repeated low­dose challenge with pathogenic simian immunodeficiency 
virus SIVmac239. J. Virol. 80:5875–5885. 
  19.  Mothe,  B.R.,  H.  Horton,  D.K.  Carter,  T.M.  Allen,  M.E.  Liebl,  P. 
Skinner, T.U. Vogel, S. Fuenger, K. Vielhuber, W. Rehrauer, et al. 2002. 
Dominance of CD8 responses specific for epitopes bound by a single major 
histocompatibility complex class I molecule during the acute phase of viral 
infection. J. Virol. 76:875–884. 
  20. Venturi, V., D.A. Price, D.C. Douek, and M.P. Davenport. 2008. 
The molecular basis for public T­cell responses? Nat. Rev. Immunol. 
8:231–238. 
  21. Betts, M.R., B. Exley, D.A. Price, A. Bansal, Z.T. Camacho, V. 
Teaberry, S.M. West, D.R. Ambrozak, G. Tomaras, M. Roederer,   
et al. 2005. Characterization of functional and phenotypic changes 
in  anti­Gag  vaccine­induced  T  cell  responses  and  their  role  in 
protection after HIV­1 infection. Proc. Natl. Acad. Sci. USA. 102: 
4512–4517. 
  22.  Smith, M.Z., T.E. Asher, V. Venturi, M.P. Davenport, D.C. Douek, D.A. 
Price, and S.J. Kent. 2008. Limited maintenance of vaccine­induced sim­
ian immunodeficiency virus­specific CD8 T­cell receptor clonotypes after 
virus challenge. J. Virol. 82:7357–7368. 
  23.  Venturi,  V.,  K.  Kedzierska,  S.J.  Turner,  P.C.  Doherty,  and  M.P. 
Davenport. 2007. Methods for comparing the diversity of samples of 
the T cell receptor repertoire. J. Immunol. Methods. 321:182–195. 
  24.  Meyer­Olson, D., N.H. Shoukry, K.W. Brady, H. Kim, D.P. Olson, K. 
Hartman, A.K. Shintani, C.M. Walker, and S.A. Kalams. 2004. Limited 
T cell receptor diversity of HCV­specific T cell responses is associated 
with CTL escape. J. Exp. Med. 200:307–319. 
  25. Peyerl, F.W., D.H. Barouch, W.W. Yeh, H.S. Bazick, J. Kunstman, 
K.J.  Kunstman,  S.M.  Wolinsky,  and  N.L.  Letvin.  2003.  Simian­
human immunodeficiency virus escape from cytotoxic T­lympho­
cyte recognition at a structurally constrained epitope. J. Virol. 77: 
12572–12578. 
  26. Peyerl,  F.W.,  H.S.  Bazick,  M.H.  Newberg,  D.H.  Barouch,  J. 
Sodroski, and N.L. Letvin. 2004. Fitness costs limit viral escape from 
cytotoxic T lymphocytes at a structurally constrained epitope. J. Virol. 
78:13901–13910. 
  27.  Mattapallil, J.J., D.C. Douek, A. Buckler­White, D. Montefiori, N.L. 
Letvin, G.J. Nabel, and M. Roederer. 2006. Vaccination preserves CD4 
memory T cells during acute simian immunodeficiency virus challenge. 
J. Exp. Med. 203:1533–1541. 
  28.  Letvin, N.L., J.R. Mascola, Y. Sun, D.A. Gorgone, A.P. Buzby, L. Xu, 
Z.Y. Yang, B. Chakrabarti, S.S. Rao, J.E. Schmitz, et al. 2006. Preserved 
were observed in the functional profile of CM9­specific CD8+ T cells ir­
respective of virologic outcome. Fig. S3 shows the antigen sensitivity and 
cross­reactivity  profiles  of  CM9­specific  CD8+  T  cell  populations  from 
four macaques at week 2 after vaccination with Ad5; consistent with the 
data shown in Fig. 6, CM9­specific CD8+ T cell populations that were 
enriched for public clonotypes exhibited greater levels of cross­reactivity 
in response to both natural and selected monosubstituted peptide epitope 
variants. Table S2 displays the 3 sequences of expressed TCRBV13 family   
genes. Online supplemental material is available at http://www.jem.org/ 
cgi/content/full/jem.20081127/DC1.
This work was supported by the Intramural Research Program of the Vaccine Research 
Center, National Institute of Allergy and Infectious Diseases, National Institutes of 
Health, and by the Australian Research Council. D.A. Price is a Medical Research 
Council (UK) Senior Clinical Fellow. M.P. Davenport is a Sylvia and Charles Viertel 
Senior Medical Research Fellow.
The authors have no conflicting financial interests.
Submitted: 23 May 2008
Accepted: 16 March 2009
REFERENCES
  1.  Sekaly, R.P. 2008. The failed HIV Merck vaccine study: a step back 
or a launching point for future vaccine development? J. Exp. Med. 
205:7–12. 
  2.  Watkins, D.I., D.R. Burton, E.G. Kallas, J.P. Moore, and W.C. Koff. 
2008. Nonhuman primate models and the failure of the Merck HIV­1 
vaccine in humans. Nat. Med. 14:617–621. 
  3.  Appay, V., D.C. Douek, and D.A. Price. 2008. CD8+ T cell efficacy in 
vaccination and disease. Nat. Med. 14:623–628. 
  4.  Sewell, A.K., D.A. Price, A. Oxenius, A.D. Kelleher, and R.E. Phillips. 
2000. Cytotoxic T lymphocyte responses to human immunodeficiency vi­
rus: control and escape. Stem Cells. 18:230–244. 
  5.  Scherer, A., J. Frater, A. Oxenius, J. Agudelo, D.A. Price, H.F. Gunthard, 
M. Barnardo, L. Perrin, B. Hirschel, R.E. Phillips, and A.R. McLean. 2004. 
Quantifiable cytotoxic T lymphocyte responses and HLA­related risk of 
progression to AIDS. Proc. Natl. Acad. Sci. USA. 101:12266–12270. 
  6.  Goulder, P.J., and D.I. Watkins. 2008. Impact of MHC class I diversity 
on immune control of immunodeficiency virus replication. Nat. Rev. 
Immunol. 8:619–630. 
  7.  Betts, M.R., D.R. Ambrozak, D.C. Douek, S. Bonhoeffer, J.M. Brenchley, 
J.P. Casazza, R.A. Koup, and L.J. Picker. 2001. Analysis of total human 
immunodeficiency virus (HIV)­specific CD4(+) and CD8(+) T­cell re­
sponses:  relationship  to  viral  load  in  untreated  HIV infection. J.  Virol. 
75:11983–11991. 
 8.  Addo, M.M., X.G. Yu, A. Rathod, D. Cohen, R.L. Eldridge, D. 
Strick, M.N. Johnston, C. Corcoran, A.G. Wurcel, C.A. Fitzpatrick, et al. 
2003. Comprehensive epitope analysis of human immunodeficiency 
virus type 1 (HIV­1)­specific T­cell responses directed against the entire 
expressed HIV­1 genome demonstrate broadly directed responses, but 
no correlation to viral load. J. Virol. 77:2081–2092. 
  9.  Casimiro, D.R., F. Wang, W.A. Schleif, X. Liang, Z.Q. Zhang, T.W. 
Tobery, M.E. Davies, A.B. McDermott, D.H. O’Connor, A. Fridman, 
et al. 2005. Attenuation of simian immunodeficiency virus SIVmac239 
infection by prophylactic immunization with DNA and recombinant 
adenoviral vaccine vectors expressing Gag. J. Virol. 79:15547–15555. 
  10.  Moniuszko, M., D. Bogdan, R. Pal, D. Venzon, L. Stevceva, J. Nacsa, 
E. Tryniszewska, Y. Edghill­Smith, S.M. Wolinsky, and G. Franchini. 
2005. Correlation between viral RNA levels but not immune responses 
in plasma and tissues of macaques with long­standing SIVmac251 infec­
tion. Virology. 333:159–168. 
  11.  Betts, M.R., M.C. Nason, S.M. West, S.C. De Rosa, S.A. Migueles, J. 
Abraham, M.M. Lederman, J.M. Benito, P.A. Goepfert, M. Connors, 
et al. 2006. HIV nonprogressors preferentially maintain highly func­
tional HIV­specific CD8+ T cells. Blood. 107:4781–4789. 
  12.  Almeida, J.R., D.A. Price, L. Papagno, Z.A. Arkoub, D. Sauce, E. 
Bornstein, T.E. Asher, A. Samri, A. Schnuriger, I. Theodorou, et al. 
2007. Superior control of HIV­1 replication by CD8+ T cells is reflected JEM VOL. 206, April 13, 2009 
ARTICLE
935
CD4+ central memory T cells and survival in vaccinated SIV­challenged 
monkeys. Science. 312:1530–1533. 
  29.  Allen, T.M., D.H. O’Connor, P. Jing, J.L. Dzuris, B.R. Mothe, T.U. 
Vogel, E. Dunphy, M.E. Liebl, C. Emerson, N. Wilson, et al. 2000. Tat­
specific cytotoxic T lymphocytes select for SIV escape variants during 
resolution of primary viraemia. Nature. 407:386–390.
  30.  Allen, T.M., L. Mortara, B.R. Mothe, M. Liebl, P. Jing, B. Calore, M. 
Piekarczyk, R. Ruddersdorf, D.H. O’Connor, X. Wang, et al. 2002. 
Tat­vaccinated macaques do not control simian immunodeficiency vi­
rus SIVmac239 replication. J. Virol. 76:4108–4112. 
  31.  Friedrich, T.C., E.J. Dodds, L.J. Yant, L. Vojnov, R. Rudersdorf, C. 
Cullen, D.T. Evans, R.C. Desrosiers, B.R. Mothe, J. Sidney, et al. 
2004. Reversion of CTL escape­variant immunodeficiency viruses in 
vivo. Nat. Med. 10:275–281. 
  32.  Chu, F., Z. Lou, Y.W. Chen, Y. Liu, B. Gao, L. Zong, A.H. Khan, J.I. 
Bell, Z. Rao, and G.F. Gao. 2007. First glimpse of the peptide presenta­
tion by rhesus macaque MHC class I: crystal structures of Mamu­A*01 
complexed with two immunogenic SIV epitopes and insights into CTL 
escape. J. Immunol. 178:944–952.
  33.  Champagne, P., G.S. Ogg, A.S. King, C. Knabenhans, K. Ellefsen, 
M. Nobile, V. Appay, G.P. Rizzardi, S. Fleury, M. Lipp, et al. 2001. 
Skewed  maturation  of  memory  HIV­specific  CD8  T  lymphocytes. 
Nature. 410:106–111. 
  34.  Mueller, Y.M., S.C. De Rosa, J.A. Hutton, J. Witek, M. Roederer, 
J.D. Altman, and P.D. Katsikis. 2001. Increased CD95/Fas­induced 
apoptosis of HIV­specific CD8(+) T cells. Immunity. 15:871–882. 
  35.  La Gruta, N.L., P.G. Thomas, A.I. Webb, M.A. Dunstone, T. Cukalac, 
P.C.  Doherty,  A.W.  Purcell,  J.  Rossjohn,  and  S.J.  Turner.  2008. 
Epitope­specific  TCRbeta  repertoire  diversity  imparts  no  functional 
advantage on the CD8+ T cell response to cognate viral peptides. Proc. 
Natl. Acad. Sci. USA. 105:2034–2039. 
  36.  Mason, D. 1998. A very high level of crossreactivity is an essential fea­
ture of the T­cell receptor. Immunol. Today. 19:395–404. 
  37.  Selin, L.K., M. Cornberg, M.A. Brehm, S.K. Kim, C. Calcagno, D. 
Ghersi, R. Puzone, F. Celada, and R.M. Welsh. 2004. CD8 memory 
T cells: cross­reactivity and heterologous immunity. Semin. Immunol. 
16:335–347. 
  38.  Brenchley, J.M., L.E. Ruff, J.P. Casazza, R.A. Koup, D.A. Price, and 
D.C. Douek. 2006. Preferential infection shortens the life span of 
human immunodeficiency virus­specific CD4+ T cells in vivo. J. Virol. 
80:6801–6809. 
  39.  Davenport, M.P., D.A. Price, and A.J. McMichael. 2007. The T cell 
repertoire in infection and vaccination: implications for control of per­
sistent viruses. Curr. Opin. Immunol. 19:294–300. 
  40.  Charini, W.A., M.J. Kuroda, J.E. Schmitz, K.R. Beaudry, W. Lin, M.A. 
Lifton, G.R. Krivulka, A. Necker, and N.L. Letvin. 2001. Clonally di­
verse CTL response to a dominant viral epitope recognizes potential 
epitope variants. J. Immunol. 167:4996–5003.
  41.  Douek, D.C., M.R. Betts, J.M. Brenchley, B.J. Hill, D.R. Ambrozak, 
K.L. Ngai, N.J. Karandikar, J.P. Casazza, and R.A. Koup. 2002. A novel 
approach to the analysis of specificity, clonality, and frequency of HIV­
specific T cell responses reveals a potential mechanism for control of viral 
escape. J. Immunol. 168:3099–3104.
  42.  Meyer­Olson, D., K.W. Brady, M.T. Bartman, K.M. O’Sullivan, B.C. 
Simons, J.A. Conrad, C.B. Duncan, S. Lorey, A. Siddique, R. Draenert, 
et  al.  2006.  Fluctuations  of  functionally  distinct  CD8+  T­cell  clono­
types demonstrate flexibility of the HIV­specific TCR repertoire. Blood. 
107:2373–2383. 
  43. Reiser, J.B., C. Darnault, C. Gregoire, T. Mosser, G. Mazza, A. 
Kearney, P.A. van der Merwe, J.C. Fontecilla­Camps, D. Housset, and 
B. Malissen. 2003. CDR3 loop flexibility contributes to the degeneracy 
of TCR recognition. Nat. Immunol. 4:241–247. 
  44.  Turnbull, E.L., A.R. Lopes, N.A. Jones, D. Cornforth, P. Newton, D. 
Aldam, P. Pellegrino, J. Turner, I. Williams, C.M. Wilson, et al. 2006. 
HIV­1 epitope­specific CD8+ T cell responses strongly associated with 
delayed disease progression cross­recognize epitope variants efficiently. 
J. Immunol. 176:6130–6146.
  45. Dong, T., G. Stewart­Jones, N. Chen, P. Easterbrook, X. Xu, L. 
Papagno, V. Appay, M. Weekes, C. Conlon, C. Spina, et al. 2004. 
HIV­specific cytotoxic T cells from long­term survivors select a unique 
T cell receptor. J. Exp. Med. 200:1547–1557. 
  46.  Brenchley, J.M., D.A. Price, and D.C. Douek. 2006. HIV disease: fall­
out from a mucosal catastrophe? Nat. Immunol. 7:235–239. 
  47.  Venturi, V., K. Kedzierska, D.A. Price, P.C. Doherty, D.C. Douek, 
S.J. Turner, and M.P. Davenport. 2006. Sharing of T cell receptors in 
antigen­specific responses is driven by convergent recombination. Proc. 
Natl. Acad. Sci. USA. 103:18691–18696. 
  48.  Venturi, V., H.Y. Chin, D.A. Price, D.C. Douek, and M.P. Davenport. 
2008. The role of production frequency in the sharing of simian immuno­
deficiency virus­specific CD8+ TCRs between macaques. J. Immunol. 
181:2597–2609.
  49. Venturi, V., H.Y. Chin, T.E. Asher, K. Ladell, P. Scheinberg, E. 
Bornstein, D. van Bockel, A.D. Kelleher, D.C. Douek, D.A. Price, 
and  M.P.  Davenport.  2008.  TCR  beta­chain  sharing  in  human 
CD8+ T cell responses to cytomegalovirus and EBV. J. Immunol. 
181:7853–7862.
  50.  Cohen, I.R. 1992. The cognitive paradigm and the immunological ho­
munculus. Immunol. Today. 13:490–494. 
  51.  Davenport, M.P., C. Fazou, A.J. McMichael, and M.F. Callan. 2002. 
Clonal selection, clonal senescence, and clonal succession: the evolu­
tion of the T cell response to infection with a persistent virus. J. Immunol. 
168:3309–3317.
  52.  Pantaleo, G., J.F. Demarest, T. Schacker, M. Vaccarezza, O.J. Cohen, 
M. Daucher, C. Graziosi, S.S. Schnittman, T.C. Quinn, G.M. Shaw,   
et al. 1997. The qualitative nature of the primary immune response 
to HIV infection is a prognosticator of disease progression indepen­
dent of the initial level of plasma viremia. Proc. Natl. Acad. Sci. USA. 
94:254–258. 
  53. Vezys, V., D. Masopust, C.C. Kemball, D.L. Barber, L.A. O’Mara, 
C.P. Larsen, T.C. Pearson, R. Ahmed, and A.E. Lukacher. 2006. 
Continuous recruitment of naive T cells contributes to heterogene­
ity of antiviral CD8 T cells during persistent infection. J. Exp. Med. 
203:2263–2269. 
  54.  Burrows, S.R., S.L. Silins, D.J. Moss, R. Khanna, I.S. Misko, and V.P. 
Argaet. 1995. T cell receptor repertoire for a viral epitope in humans is 
diversified by tolerance to a background major histocompatibility com­
plex antigen. J. Exp. Med. 182:1703–1715. 
  55.  Shiver, J.W., T.M. Fu, L. Chen, D.R. Casimiro, M.E. Davies, R.K. 
Evans, Z.Q. Zhang, A.J. Simon, W.L. Trigona, S.A. Dubey, et al. 2002. 
Replication­incompetent adenoviral vaccine vector elicits effective anti­
immunodeficiency­virus immunity. Nature. 415:331–335. 
  56.  McDermott, A.B., J. Mitchen, S. Piaskowski, I. De Souza, L.J. Yant, 
J. Stephany, J. Furlott, and D.I. Watkins. 2004. Repeated low­dose 
mucosal simian immunodeficiency virus SIVmac239 challenge results 
in the same viral and immunological kinetics as high­dose challenge: 
a model for the evaluation of vaccine efficacy in nonhuman primates.  
J. Virol. 78:3140–3144. 
  57. Lifson,  J.D.,  J.L.  Rossio,  R.  Arnaout,  L.  Li,  T.L.  Parks,  D.K. 
Schneider, R.F. Kiser, V.J. Coalter, G. Walsh, R.J. Imming, et al. 
2000.  Containment  of  simian  immunodeficiency  virus  infection: 
cellular immune responses and protection from rechallenge follow­
ing transient postinoculation antiretroviral treatment. J. Virol. 74: 
2584–2593. 
  58.  Lifson, J.D., J.L. Rossio, M. Piatak Jr., T. Parks, L. Li, R. Kiser, V. 
Coalter, B. Fisher, B.M. Flynn, S. Czajak, et al. 2001. Role of CD8(+) 
lymphocytes in control of simian immunodeficiency virus infection and 
resistance to rechallenge after transient early antiretroviral treatment.   
J. Virol. 75:10187–10199. 
  59.  Allen, T.M., B.R. Mothe, J. Sidney, P. Jing, J.L. Dzuris, M.E. Liebl, T.U. 
Vogel, D.H. O’Connor, X. Wang, M.C. Wussow, et al. 2001. CD8(+) 
lymphocytes  from  simian  immunodeficiency  virus­infected  rhesus  ma­
caques recognize 14 different epitopes bound by the major histocompatibil­
ity complex class I molecule mamu­A*01: implications for vaccine design 
and testing. J. Virol. 75:738–749. 
  60.  Lee, J.K., G. Stewart­Jones, T. Dong, K. Harlos, K. Di Gleria, L. Dorrell, 
D.C. Douek, P.A. van der Merwe, E.Y. Jones, and A.J. McMichael. 
2004. T cell cross­reactivity and conformational changes during TCR 
engagement. J. Exp. Med. 200:1455–1466. 936 CLONOTYPIC DETERMINANTS OF PROTECTIVE CD8+ T CELL RESPONSES | Price et al.
  61.  Kuroda, M.J., J.E. Schmitz, D.H. Barouch, A. Craiu, T.M. Allen, A. 
Sette, D.I. Watkins, M.A. Forman, and N.L. Letvin. 1998. Analysis 
of Gag­specific cytotoxic T lymphocytes in simian immunodeficiency 
virus–infected rhesus monkeys by cell staining with a tetrameric ma­
jor histocompatibility complex class I–peptide complex. J. Exp. Med. 
187:1373–1381. 
  62.  Wille­Reece,  U.,  B.J.  Flynn,  K.  Lore,  R.A.  Koup,  R.M.  Kedl,  J.J. 
Mattapallil, W.R. Weiss, M. Roederer, and R.A. Seder. 2005. HIV Gag 
protein conjugated to a Toll­like receptor 7/8 agonist improves the mag­
nitude and quality of Th1 and CD8+ T cell responses in nonhuman pri­
mates. Proc. Natl. Acad. Sci. USA. 102:15190–15194. 
  63.  Price,  D.A.,  J.M.  Brenchley,  L.E.  Ruff,  M.R.  Betts,  B.J.  Hill,  M. 
Roederer,  R.A.  Koup,  S.A.  Migueles,  E.  Gostick,  L.  Wooldridge, 
et  al.  2005.  Avidity  for  antigen  shapes  clonal  dominance  in  CD8+ 
T cell populations specific for persistent DNA viruses. J. Exp. Med. 
202:1349–1361. 
  64.  Arden, B., S.P. Clark, D. Kabelitz, and T.W. Mak. 1995. Human T­cell 
receptor variable gene segment families. Immunogenetics. 42:455–500.